丙型肝炎病毒及干扰素引起的心血管不良反应被引量：1

Cardiovascular Adverse Reactions Generated by HCV and Interferon

导出

摘要在干扰素治疗丙型肝炎的临床使用中已出现心血管不良事件的报道,但多为个案报道,经报道的患者几乎均为接受高剂量干扰素治疗、本身有心脏疾病或以前接受造成心脏损害药物治疗的患者。而丙型肝炎病毒本身可通过刺激机体产生细胞因子、诱导心肌线粒体损伤等众多途径对心肌造成损伤,其极易变异,可逃避宿主免疫而长期存在于人体内。故干扰素引起心血管不良反应可能被夸大了。在治疗过程中,如定期监测心功能的敏感指标(如心肌肌钙蛋白),发现异常尽早对症处理,干扰素的使用将是安全的。 Cardiovascular events occurrence during the clinical use of interferon treatment of hepatitis C have been reported, but mostly are occasional cases of patients receiving high-dose interferon treatment or with a history of heart disease or having previously been given ebemotherapy with drugs known to be eardio- toxic. Meanwhile HCV （hepatitis c virus） can damage the heart by stimulating the production of eytokines, inducing myocardial mitoehondria loss etc. , which may easily mutatw, and can evade the host immune and exist in the human body for long. Therefore interferon causing cardiovascular adverse reaction may be exagger- ated. In the course of treatment, should regular monitoring of the sensitive index such as myocardial troponin be done and corresponding treatment he given in time, the use of interferon will be safe.

作者韦婷婷陈红邓永东

机构地区兰州大学第一医院感染科

出处《医学综述》 2014年第1期74-77,共4页 Medical Recapitulate

关键词丙型肝炎病毒干扰素心血管不良反应心律失常 Hepatitis C virus Interferon Cardiovascular adverse reaction Arrhythmia

分类号 R473.5 [医药卫生—护理学]

引文网络
相关文献

参考文献24

1Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a bloodbornc non-A, non-B viral hepatitis geuome [ J ]. Science, 1989,244 (4902) : 359 -362.
2Matsumori A, Ohashi N, Hasegawa K, et al. Hepatitis C virus infec- tion and heart diseases:A multicenter study in Japan[ J]. Jpn Circ J,1998,62(5) :389-391.
3Matsumori A,Yutani C, Ikcda Y, et al. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy [ J ]. Lab Invest,2000,80 (7) :1137-1142.
4Vecile E, Dobrina A, Salloum FN, et al. Intracellular function of interleukin-1 receptor antagonist in ischemic cardiomyocytes [ J ]. PLoS One,2013,8( 1 ) :e53265.
5Cruise MW, Melief HM, Lukens J, et al. Increased Fas ligand expression of CD4+ T cells by HCV core induces T cell-dependent hepatic inflammation [ J ]. J Leukoc Bio1,2005,78 (2) :412-425.
6Peng YS,Chiang CK, Hsu SP, et al. Influence of hepatitis C virus inf eetion on soluble cellular adhesion molecules in hemodialysis patients [J]. Blood Purif,2005,23 ( 2 ) : 106-112.
7Sasayama S, Matsumori A, Kihara Y. New insights into the patho- physiological role for eytokines in heart failure [ J ]. Cardiovase Res, 1999,42 ( 3 ) :557-564.
8Tardif KD,Waris G, Siddiqui A. Hepatitis C virus, ER stress, and oxidative stress[ J ]. Trends Mierobio1,2005,13 (4) : 159-163.
9Omura T, Yoshiyama M, Yoshida K, et al. Dominant negative mutant of e-Jan inhibits eardiomyoeyte hypertrophy induced by endothelin 1 and phenylephrine [ J ]. Hypertension,2002,39 ( 1 ) :81-86.
10Arbustini E, Diegoli M, Fasani R, et al. Mitoehondrial DNA muta- tions and mitochondrial abnormalities in dilated eardiomyopathy [J]. Am J Pathol,1998,153(5) :1501-1510.